World ADC Presentation 2017

Abzena’s presentation at World ADC 2017 given by Campbell Bunce – Senior Vice President Technical Operations.


Optimisation of Pharmacokinetics Fact Sheet

Information on a our PEGylation technologies, including a TheraPEG case study on the PEGylation of interferon (IFN) a-2b




Design and Synthesis of Isoquinolidinobenzodiazepine Dimers, a Novel Class of Antibody–Drug Conjugate Payload

Antibody–drug conjugates (ADCs) represent an important class of emerging cancer therapeutics. Recent ADC development[...] Read more

Modulation of drug-linker design to enhance in vivo potency of homogeneous antibody-drug conjugates

Antibody-drug conjugates (ADCs) are a promising class of anticancer agents which have undergone substantial development[...] Read more

Stable and Homogeneous Drug Conjugation by Sequential Bis-Alkylation at Disulphide Bonds Using Bis-Sulphone Reagents

Antibody drug conjugates (ADCs) have begun to have a tremendous impact on the treatment of cancer and other pathological[...] Read more

In vitro and in vivo evaluation of cysteine rebridged trastuzumab–MMAE antibody drug conjugates with defined drug-to-antibody ratios

Penny Bryant, Martin Pabst, George Badescu, Matthew Bird, William McDowell, Estera Jamieson, Julia Swierkosz, Kosma[...] Read more

Conjugation of PolyPEG to Interferon Alpha Extends Serum Half-Life while Maintaining Low Viscosity of the Conjugate

B. Podobnik, B. Helk, V. Smilović, Š. Škrajnar, K. Fidler, S. Jevševar, A. Godwin, and P. Williams. Bioconjugate[...] Read more

Technology Advances Enable Creation of Better ADCs

Technology Advances Enable Creation of Better ADCs Waterman.  BioProcess International. 2014; 12(9)s: 37-40 Read more

A New Reagent for Stable Thiol-Specific Conjugation

George Badescu, Penny Bryant, Julia Swierkosz, Farzad Khayrzad, Estera Pawlisz, Monika Farys, Yuehua Cong, Maurizio[...] Read more

Bridging Disulfides for Stable and Defined Antibody Drug Conjugates

George Badescu, Penny Bryant, Matthew Bird, Korinna Henseleit, Julia Swierkosz, Vimal Parekh, Rita Tommasi, Estera[...] Read more

Bridging the Conjugation Gap: Maintaining Disulfide Bridges Leads to Improved Homogeneity and Stability for ADCs

Antony Godwin. Genetic Engineering & Biotechnology News. January 2013, 33(3): 20-21. doi:10.1089/gen.33.3.10. A new[...] Read more


Abzena announced as best CRO at World ADC awards

Cambridge, UK and San Diego, CA, 17th September 2020 – Abzena, a fully integrated global development and GMP[...] Read more

Abzena offers integrated clinical translation of biologics with launch of ADC Cascade and Biologics Cascade

Cambridge, UK 07 October 2019 – Abzena, the leading biologics target to GMP Partner Research Organisation, announced it[...] Read more

Abzena announces successful technical transfer of Synaffix GlycoConnect™ Antibody Drug Conjugate (ADC) technology to enable use in client projects

San Diego, USA July 2019 – Abzena, the global partner research organization, announced it has successfully completed a[...] Read more

Abzena Announces New Fully Integrated Developability and Optimization Service to Improve Lead Selection and De-risk Biologic Cell Line Development

Cambridge, UK 21 March 2019 – Abzena, the leading biologics target to GMP partner research organisation (PRO),[...] Read more

Abzena and Telix sign strategic manufacturing and bioconjugation agreement

Cambridge, UK and Melbourne, Australia, 2 July 2018 – Abzena plc (AIM: ABZA, ‘Abzena’), the life sciences group[...] Read more

Facility Remodelling Completed for Abzena’s New Antibody-Drug Conjugate GMP Manufacturing Suite

CAMBRIDGE, England & BRISTOL, PA, USA, Abzena plc, the life sciences group providing services and technologies to[...] Read more

Interested in our services? Get In Touch